IMDC Risk Model for Metastatic RCC
The IMDC risk model stratifies metastatic renal cell carcinoma patients into favorable, intermediate, or poor prognostic groups based on six clinical and laboratory factors.
Indications for Use
Used for adults with metastatic RCC before starting systemic therapy to stratify prognosis into favorable, intermediate, or poor risk, guiding first‑line regimen selection, counseling on expected survival, and clinical‑trial stratification per ESMO/NCCN [1](https://doi.org/10.1016/j.annonc.2024.05.537\) [Level I evidence]; [2](https://doi.org/10.6004/jnccn.2022.0001\) [Level I evidence]. Continues to discriminate outcomes even with modern IO‑based combinations [3](https://doi.org/10.1016/j.eururo.2023.01.001\) [Level II evidence].
Insights & Cautions
Assigns prognosis for metastatic RCC using six adverse factors (KPS <80%, low hemoglobin, high calcium, neutrophilia, thrombocytosis, diagnosis‑to‑treatment <1 year). Strongly validated across VEGFR‑TKI and ICI eras with consistent discrimination (C‑index ~0.66) and survival separation 1 [Level II evidence]. Use cautiously: derived in targeted‑therapy era, less predictive for ICI response 2 [Level I evidence], and does not account for metastatic pattern or molecular features.